5 Best Biotech Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund

Page 5 of 5

1. argenx SE (NASDAQ:ARGX)

Biotechnology Value Fund’s Stake Value: $196,058,000
Percent of Biotechnology Value Fund’s 13F Portfolio: 7.34%
Number of Hedge Fund Holders: 27

argenx SE (NASDAQ:ARGX) is a Dutch biotechnology company aimed at developing antibody-based therapies for severe autoimmune diseases and cancer.

In Q2 2021, the Biotechnology Value Fund increased its position in argenx SE (NASDAQ:ARGX) by 111% and now holds 651,204 shares in the company, valued at over $196 million. The company represents 7.34% of the hedge fund’s 13F portfolio.

Recently, Jefferies initiated its coverage on argenx SE (NASDAQ:ARGX) with a Buy rating and a $362 price target. As of Q2 2021, 27 hedge funds tracked by Insider Monkey reported having stakes in argenx SE (NASDAQ:ARGX), the same as in the previous quarter. The total value of these stakes is $1.45 billion.

Artisan Partners mentioned argenx SE (NASDAQ:ARGX) in its Q2 2021 investor letter. Here is what the firm has to say:

Argenx is a Dutch biotechnology company developing antibodybased therapies for autoimmune diseases and cancer. Commercial preparations are underway for the company’s FcRn drug efgartigimod, which is used to treat patients with severe autoimmune diseases. Discussions with health insurance payers have been positive, and the manufacturing/supply chain is well-positioned. Argenx appears to be not only first-in-class (a first mover) but also the best-inclass asset in a high value and competitive field of FcRn drugs. First-inclass drugs typically take the majority of market share, and with a best-in-class profile, Argenx could solidify a dominate market position.”

You can also take a look at 12 Best Large-cap Biotech Stocks To Buy Now and 10 Best Biotech Stocks To Invest In

Page 5 of 5